M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers BioPharma DiveEquipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.M&A / DealsImmunology & InflammationRead full story pharminent April 15, 2026 (Last updated: April 16, 2026) BioPharma Dive Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases. M&A / DealsImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere wins long-awaited approval for kidney disease drugNext: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
